RT editorial T1 RhoA in aneurysmal subarachnoid hemorrhage A1 Ureña, Juan A1 González Montelongo, María del Carmen A1 Murillo Cabezas, Francisco A2 BiomedicinaBiotecnología y Salud Pública K1 RhoA K1 biomarker K1 cerebral vasospasm K1 human mononuclear cells K1 subarachnoid haemorrhage AB Aneurysmal subarachnoid haemorrhage (aSAH) is a severe subtype of stroke, mediated by the spontaneous rupture of an intracranial aneurysm, that frequently occurs in people between 40 and 60 years of age. Cerebral vasospasm (CV), and related delayed cerebral ischemia (DCI), is a clinical syndrome of the focal neurologic deficits that develop typically three to fourteen days after the aneurysm rupture, and is a major cause of death and disability after aSAH. Vascular constriction and inflammation, more specifically leukocyte-endothelium interaction, appear to play a critical role in CV. Although the main focus of pharmacological treatment of aSAH is the prevention of DCI, the only pharmacological drug shown to reduce the risk of DCI and unfavourable outcome is nimodipine, an L-type Ca2+ channels (LTCCs) antagonist, which does not alter the incidence or severity of CV [1]. On the other hand, although inflammatory biomarkers that facilitate leukocyte-endothelium interaction have been found in the cerebral spinal fluid and serum of patients [2], none of these biomarkers have been shown to be useful tools for predicting CV development or outcome after aSAH. Therefore, it is necessary to study new pathophysiological pathways to improve outcomes and management of patients. YR 2019 FD 2019 LK http://hdl.handle.net/10498/31634 UL http://hdl.handle.net/10498/31634 LA eng DS Repositorio Institucional de la Universidad de Cádiz RD 16-nov-2026